Ham-milton
Bluelighter
- Joined
- Jul 20, 2007
- Messages
- 5,738
This originally said something different, but no one had any predictions, which is fine, because Murphy (aka my personal jesus) uploaded this paper for me:
Neurochemical evidence for antidepressant effects of T. catigua extract
The antidepressant-like activity of T. catigua extract was further confirmed by monoamine uptake and release experiments. A one-way ANOVA analysis showed that T. catigua extract (10–300 μg/ml) reduced, in a significant manner, the synaptosomal uptake of [3H]dopamine [F(5,12)=85.1, P<0.01] or [3H]serotonin [F(5,12)=27.2, P<0.01] in membrane preparations from rats. The extract of T. catigua significantly reduced the uptake of [3H]dopamine when assessed in the concentrations of 10, 30, 100 and 300 μg/ml (Fig. 4), whereas it significantly affected the uptake of [3H]serotonin only at the concentrations of 100 and 300 μg/ml (Fig. 4). The calculated mean IC50 values accompanied by the 95% confidence limits were (in μg/ml) 35 (17–73) and 68 (35–130), for dopamine and serotonin uptake, respectively. On the basis of IC50 values, the T. catigua extract was about two times more potent in inhibiting dopamine than serotonin uptake. Otherwise, T. catigua extract (10–300 μg/ml) was not able to significantly affect the synaptosomal uptake of [3H]noradrenaline [F(5,12)=10.29, P<0.05] (Fig. 5). The positive control drugs cocaine (3.4 μg/ml), fluoxetine (35 μg/ml) and desipramine (30 μg/ml) produced a marked inhibition of [3H]dopamine (Fig. 4), [3H]serotonin (Fig. 4) and [3H]noradrenaline uptake, respectively. In vitro effects of T. catigua extract on dopamine uptake were confirmed by experiments indicating that the longterm treatment of rats with T. catigua (200 mg/kg, p.o.), once a day for up to 42 days, caused a significant inhibition of [3H]dopamine uptake [one-way ANOVA: F(2,10)=9.6, P<0.01] in synaptosomal preparations (Fig. 5). On the other hand, [3H]serotonin uptake was not significantly affected by chronic treatment with T. catigua extract (Fig. 5). The results also demonstrate that chronic treatment with fluoxetine caused a significant reduction of both serotonin (Fig. 5) and dopamine (Fig. 5) uptake.
Monoamine release experiments indicated that in vitro incubation with T. catigua extract (10 to 300 μg/ml) significantly
increased the release of [3H]dopamine [one-way ANOVA: F(5,12)=285.2, P<0.01] and [3H]serotonin [oneway ANOVA: F(4,10)=19.5, P<0.01] in synaptosomal fractions obtained from rats. The extract of T. catigua increased the release of [3H]dopamine in a significant way when assessed in the concentrations of 10, 20, 40, 80, 100 and 200 μg/ml (Fig. 6), whilst it significantly enhanced the release of [3H]serotonin only at the concentrations of 100 and 300 μg/ml (Fig. 6). the calculated mean EC50 values (accompanied by the 95% confidence limits, μg/ml) were 23 (22–24) and 111 (40–309), for dopamine and serotonin release, respectively. When the EC50 values were analyzed, T. catigua extract was about fivefold more potent in inducing dopamine than serotonin release.
Neurochemical evidence for antidepressant effects of T. catigua extract
The antidepressant-like activity of T. catigua extract was further confirmed by monoamine uptake and release experiments. A one-way ANOVA analysis showed that T. catigua extract (10–300 μg/ml) reduced, in a significant manner, the synaptosomal uptake of [3H]dopamine [F(5,12)=85.1, P<0.01] or [3H]serotonin [F(5,12)=27.2, P<0.01] in membrane preparations from rats. The extract of T. catigua significantly reduced the uptake of [3H]dopamine when assessed in the concentrations of 10, 30, 100 and 300 μg/ml (Fig. 4), whereas it significantly affected the uptake of [3H]serotonin only at the concentrations of 100 and 300 μg/ml (Fig. 4). The calculated mean IC50 values accompanied by the 95% confidence limits were (in μg/ml) 35 (17–73) and 68 (35–130), for dopamine and serotonin uptake, respectively. On the basis of IC50 values, the T. catigua extract was about two times more potent in inhibiting dopamine than serotonin uptake. Otherwise, T. catigua extract (10–300 μg/ml) was not able to significantly affect the synaptosomal uptake of [3H]noradrenaline [F(5,12)=10.29, P<0.05] (Fig. 5). The positive control drugs cocaine (3.4 μg/ml), fluoxetine (35 μg/ml) and desipramine (30 μg/ml) produced a marked inhibition of [3H]dopamine (Fig. 4), [3H]serotonin (Fig. 4) and [3H]noradrenaline uptake, respectively. In vitro effects of T. catigua extract on dopamine uptake were confirmed by experiments indicating that the longterm treatment of rats with T. catigua (200 mg/kg, p.o.), once a day for up to 42 days, caused a significant inhibition of [3H]dopamine uptake [one-way ANOVA: F(2,10)=9.6, P<0.01] in synaptosomal preparations (Fig. 5). On the other hand, [3H]serotonin uptake was not significantly affected by chronic treatment with T. catigua extract (Fig. 5). The results also demonstrate that chronic treatment with fluoxetine caused a significant reduction of both serotonin (Fig. 5) and dopamine (Fig. 5) uptake.
Monoamine release experiments indicated that in vitro incubation with T. catigua extract (10 to 300 μg/ml) significantly
increased the release of [3H]dopamine [one-way ANOVA: F(5,12)=285.2, P<0.01] and [3H]serotonin [oneway ANOVA: F(4,10)=19.5, P<0.01] in synaptosomal fractions obtained from rats. The extract of T. catigua increased the release of [3H]dopamine in a significant way when assessed in the concentrations of 10, 20, 40, 80, 100 and 200 μg/ml (Fig. 6), whilst it significantly enhanced the release of [3H]serotonin only at the concentrations of 100 and 300 μg/ml (Fig. 6). the calculated mean EC50 values (accompanied by the 95% confidence limits, μg/ml) were 23 (22–24) and 111 (40–309), for dopamine and serotonin release, respectively. When the EC50 values were analyzed, T. catigua extract was about fivefold more potent in inducing dopamine than serotonin release.
Last edited:
